Obituary: Peter B. Lyons Feb. 23, 1943 – April 29, 2021
Feb. 23, 1943 – April 29, 2021
Peter B. Lyons passed away in Golden, Colorado on Friday, April 29, 2021, following a yearlong battle with cancer. Pete’s partner Peggy Lyon-Bull and his sons Daniel, David and Michael were able to join him at his side in his final hours. He leaves behind a legacy of dedication to his family, to the scientific community and to the nation for a life spent in public service.
Pete was born to Leland and Rita (nee Horblit) Lyons in Hammond Indiana, in 1943. Although born in the midwest, he spent his childhood in Boulder City, Nevada, just outside of Las Vegas, Nevada. During his time in Nevada, he developed a passion for the geology and topography of the American southwest. He was a standout student at the small high school and also excelled as a tennis player in the then sparsely populated state. He went on to become Nevada state champion in tennis while in high school. He later joked that th
Topical therapy can help safely reduce side effect of cancer treatment
Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
For the past decade, epidermal growth factor receptor (EGFR) inhibitors have helped prolong the lives of patients with many advanced cancers, including cancers in the lung, head and neck, colorectal, breast, bladder and pancreas. While these targeted therapy drugs are highly effective at keeping the cancer at bay, they can cause patients to develop acneiform lesions, a type of skin rash that looks like acne bumps and frequently leads to impaired quality of life and drug discontinuation.
E-Mail
LOS ANGELES - Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
For the past decade, epidermal growth factor receptor (EGFR) inhibitors have helped prolong the lives of patients with many advanced cancers, including cancers in the lung, head and neck, colorectal, breast, bladder and pancreas. While these targeted therapy drugs are highly effective at keeping the cancer at bay, they can cause patients to develop acneiform lesions, a type of skin rash that looks like acne bumps and frequently leads to impaired quality of life and drug discontinuation.
Top cancer researchers convene in Beersheva
World-class experts from Israel and New York’s Memorial Sloan Kettering Cancer Center explore new frontiers in research and treatment.
Soroka Medical Center hosted the binational conference.
What are the connections between breast cancer and bone health, breast cancer and heredity, and obesity and cancer risk? Top Israeli and American experts gathered at Soroka Medical Center in Beersheva on April 2 to share new frontiers in cancer research and therapy that are changing our understanding of the disease dramatically.
The Israeli venue for a major meeting of medical minds was an obvious choice, according to conference co-chair Dr. Larry Norton, medical director of the Evelyn Lauder Breast Center at Memorial Sloan Kettering Cancer Center.
Share this article
Share this article
WALTHAM, Mass., April 20, 2021 /PRNewswire/ Syndax Pharmaceuticals, Inc. ( Syndax, the Company or we ) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company s highly selective, oral menin inhibitor. Information on how to access the live video webcast and accompanying slide presentation can be found below. Data reported today further support the potential for SNDX-5613 to induce clinically meaningful responses in patients with genetically-defined acute leukemias, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. Notably, robust clinical activity, including multiple complet